Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Volitionrx Ltd (VNRX)

Volitionrx Ltd (VNRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 25,864
  • Shares Outstanding, K 158,481
  • Annual Sales, $ 1,730 K
  • Annual Income, $ -23,360 K
  • EBIT $ -22 M
  • EBITDA $ -19 M
  • 60-Month Beta 1.33
  • Price/Sales 16.41
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.21
  • Most Recent Earnings $-0.05 on 03/31/26
  • Next Earnings Date 05/21/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 583.80% (-156.12%)
  • Historical Volatility 75.04%
  • IV Percentile 65%
  • IV Rank 33.64%
  • IV High 1,285.20% on 02/04/26
  • IV Low 228.31% on 11/12/25
  • Expected Move (DTE 24) 1.9975 (1,272.29%)
  • Put/Call Vol Ratio 0.36
  • Today's Volume 15
  • Volume Avg (30-Day) 36
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 3,106
  • Open Int (30-Day) 3,784
  • Expected Range 0.0000 to 2.1545

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.04
  • Number of Estimates 1
  • High Estimate $-0.04
  • Low Estimate $-0.04
  • Prior Year $-0.06
  • Growth Rate Est. (year over year) +33.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1502 +4.53%
on 04/07/26
0.2386 -34.20%
on 03/25/26
-0.0301 (-16.09%)
since 03/20/26
3-Month
0.1502 +4.53%
on 04/07/26
0.3149 -50.14%
on 01/30/26
-0.1345 (-46.14%)
since 01/21/26
52-Week
0.1502 +4.53%
on 04/07/26
0.9400 -83.30%
on 06/23/25
-0.3210 (-67.15%)
since 04/21/25

Most Recent Stories

More News
Volition Launches rNuQ™ Webshop Broadening Product Range

HENDERSON, Nev. , April 20, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the launch of its rNuQ webshop offering...

VNRX : 0.1570 (-3.80%)
VolitionRx Limited Announces Full Fiscal Year 2025 Financial Results and Business Update

Conference call to discuss financial and operational results scheduled for Wednesday, April 1 at 8:30 a.m. U.S. Eastern Time

VNRX : 0.1570 (-3.80%)
VolitionRx Secures EUR 2.0 Million of Non-Dilutive Funding from Regional Government Agencies in Belgium

HENDERSON, Nev. , March 31, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has secured an additional €2.0 million (approximately...

VNRX : 0.1570 (-3.80%)
Volition Announces Mayo Clinic Study Demonstrates Nu.Q® Concentrations are Elevated in Trauma Patients

Peer Reviewed Clinical Study for Nu.Q® Biomarkers Published in Shock Journal

VNRX : 0.1570 (-3.80%)
Volition Announces Abstract Demonstrating Risk Stratification in Lung Cancer Presented at the European Lung Cancer Conference

HENDERSON, Nev. , March 26, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the presentation of an abstract at the European...

VNRX : 0.1570 (-3.80%)
VolitionRx Limited Schedules Full Fiscal Year 2025 Earnings Conference Call and Business Update

Conference call to take place on Wednesday, April 1 at 8:30 a.m. U.S Eastern Time

VNRX : 0.1570 (-3.80%)
Volition Announces Detection of Over 95% of Early-Stage Cancers

HENDERSON, Nev. , March 25, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces compelling proof of concept data from a blinded...

VNRX : 0.1570 (-3.80%)
Volition Reports Breakthrough in Liquid Biopsy: Achievement of over 99% Purity in Isolating Cancer DNA

HENDERSON, Nev. , March 18, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, is the first to demonstrate the isolation and analysis...

VNRX : 0.1570 (-3.80%)
Volition Announces First Ever Automated Nu.Q® Vet Cancer Test with Fujifilm Vet Systems

HENDERSON, Nev. , March 6, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the completion of all validation and verification...

VNRX : 0.1570 (-3.80%)
VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution

HENDERSON, Nev. , Feb. 25, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, is pleased to provide a consolidated update on the significant...

VNRX : 0.1570 (-3.80%)

Business Summary

Volition RX Ltd is a life sciences company engaged in developing a range of blood-based epigenetic cancer diagnostic tests. Its tests are designed to detect the nucleosome patterns that are specific to cancer in the blood, and identify some of the major nucleosome varieties that differ between cancer...

See More

Key Turning Points

3rd Resistance Point 0.1680
2nd Resistance Point 0.1654
1st Resistance Point 0.1612
Last Price 0.1570
1st Support Level 0.1544
2nd Support Level 0.1518
3rd Support Level 0.1476

See More

52-Week High 0.9400
Fibonacci 61.8% 0.6383
Fibonacci 50% 0.5451
Fibonacci 38.2% 0.4519
Last Price 0.1570
52-Week Low 0.1502

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.